---
title: "Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294830800.md"
description: "Silexion Therapeutics reported new preclinical data for SIL204, showing it may enhance immune attack on KRAS-mutant pancreatic cancer and NSCLC cells. This supports combining SIL204 with PD-(L) 1 therapies as the drug advances into Phase 2/3 development, following the initiation of its first clinical trial site in late July 2026."
datetime: "2026-08-04T13:16:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294830800.md)
  - [en](https://longbridge.com/en/news/294830800.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294830800.md)
---

# Silexion reports preclinical SIL204 data supporting Phase 2/3 development in KRAS-driven cancers

-   Silexion Therapeutics reported new preclinical results for SIL204, extending earlier findings disclosed in May 2026. \* Studies indicated SIL204 may make KRAS-mutant pancreatic cancer and NSCLC cells more vulnerable to immune attack, supporting combination use with PD-(L) 1 therapies. \* The update comes as SIL204 advances into Phase 2⁄3 evaluation, following initiation of the first clinical trial site in late July 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608040915PRIMZONEFULLFEED1001255855) on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md)
- [SLXNW.US](https://longbridge.com/en/quote/SLXNW.US.md)

## Related News & Research

- [Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | SLXN Stock News](https://longbridge.com/en/news/295937580.md)
- [Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering | SLXN Stock News](https://longbridge.com/en/news/295592318.md)
- [GenFleet starts Phase II trial of KRAS G12D inhibitor GFH375 combos in pretreated pancreatic cancer patients](https://longbridge.com/en/news/296412333.md)
- [Granite-Integral co-leads $34 million Series D financing in Craif](https://longbridge.com/en/news/296226716.md)
- [Anixa Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference | ANIX Stock News](https://longbridge.com/en/news/296231345.md)